Stoke Therapeutics, Inc. $STOK Shares Acquired by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management increased its Stoke Therapeutics position by 24.4% in the second quarter, acquiring 221,373 shares and bringing its holdings to 1.13 million shares, or 1.81% of the company.
• Analyst sentiment remains broadly positive: nine analysts rate STOK a Buy, with an average rating of “Moderate Buy” and a consensus price target of $43. Targets range from $40 at Wedbush to $60 at Guggenheim, although Canaccord lowered its target to $58.
• Stoke reported a quarterly loss of $0.93 per share, missing the $0.80 consensus estimate, despite revenue of $9.32 million exceeding expectations. Analysts have also reduced future EPS forecasts, while insiders sold shares under pre-arranged Rule 10b5-1 plans.

Assenagon Asset Management S.A. increased its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 24.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,128,388 shares of the company's stock after purchasing an additional 221,373 shares during the quarter. Assenagon Asset Management S.A. owned 1.81% of Stoke Therapeutics worth $36,921,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new stake in Stoke Therapeutics during the fourth quarter valued at $26,000. KBC Group NV acquired a new position in shares of Stoke Therapeutics in the 1st quarter valued at about $36,000. Harbour Investments Inc. grew its position in shares of Stoke Therapeutics by 312.9% during the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company's stock valued at $38,000 after buying an additional 898 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Stoke Therapeutics by 66.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock valued at $48,000 after buying an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after acquiring an additional 3,591 shares during the period.

More Stoke Therapeutics News

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target on STOK to $40 while maintaining an “outperform” rating, signaling confidence in the company’s pipeline and potential upside. Wedbush raises Stoke Therapeutics price target
• Positive Sentiment: Chardan Capital reiterated a “buy” rating on Stoke Therapeutics, adding to the favorable analyst sentiment surrounding the biotechnology company. Chardan Capital buy rating
• Neutral Sentiment: Canaccord Genuity remained constructive on the shares but issued a more cautious price outlook, reflecting a mixed analyst view despite continued confidence in Stoke’s long-term prospects. Canaccord Genuity forecast for Stoke Therapeutics
• Negative Sentiment: HC Wainwright cut its projected EPS for fiscal 2026 to a loss of $3.35 from $3.09, fiscal 2027 to a loss of $2.55 from $2.05, and fiscal 2028 to a loss of $1.78 from $0.67. It also reduced quarterly estimates to losses of $0.81 per share, indicating expectations for higher or more prolonged expenses. HC Wainwright earnings forecast for Stoke Therapeutics
• Negative Sentiment: HC Wainwright’s broader outlook remains bearish for later years, with its FY2029 EPS forecast reportedly reduced to $1.55 from $1.63. The revisions highlight execution and commercialization risks for Stoke’s pipeline. HC Wainwright FY2029 forecast
• Negative Sentiment: Director Barry Ticho sold 7,176 shares worth approximately $208,000, reducing his direct holdings by 26%. Because the sale occurred under a pre-arranged Rule 10b5-1 plan, its negative signaling value is limited, but it may still weigh modestly on sentiment. SEC insider sale filing

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on STOK shares. The Goldman Sachs Group initiated coverage on Stoke Therapeutics in a research note on Monday, July 13th. They issued a "buy" rating and a $44.00 target price for the company. Guggenheim reiterated a "buy" rating and set a $60.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Weiss Ratings downgraded Stoke Therapeutics from a "hold (c)" rating to a "sell (d)" rating in a report on Monday, May 11th. Wedbush boosted their price objective on Stoke Therapeutics from $38.00 to $40.00 and gave the company an "outperform" rating in a research report on Tuesday, August 4th. Finally, Canaccord Genuity Group lowered their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating for the company in a research note on Tuesday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $43.00.

Insiders Place Their Bets

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 1,457 shares of the business's stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total transaction of $43,637.15. Following the completion of the transaction, the general counsel owned 18,086 shares in the company, valued at approximately $541,675.70. The trade was a 7.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 7,176 shares of Stoke Therapeutics stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $29.04, for a total transaction of $208,391.04. Following the sale, the insider owned 20,422 shares in the company, valued at approximately $593,054.88. This represents a 26.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 10,428 shares of company stock valued at $306,919 in the last quarter. 9.60% of the stock is currently owned by insiders.

Stoke Therapeutics Trading Up 2.4%

STOK opened at $32.71 on Friday. The business's 50 day moving average is $30.45 and its 200-day moving average is $32.05. The stock has a market cap of $2.11 billion, a PE ratio of -9.79 and a beta of 1.20. Stoke Therapeutics, Inc. has a twelve month low of $12.86 and a twelve month high of $40.22.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%.The business had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -3.5 EPS for the current year.

Stoke Therapeutics Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source